Pancreatic Cancer Market

DelveInsight’s ‘Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the pancreatic cancer historical and forecasted epidemiology as well as the pancreatic cancer market trends in the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The pancreatic cancer market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM pancreatic cancer market size. The report also covers current pancreatic cancer treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Geography Covered

  • The United States
  • EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Pancreatic Cancer Disease Understanding and Treatment

Pancreatic Cancer Overview

Pancreatic cancer begins in the tissues of the pancreas – an organ in the abdomen that lies behind the lower part of the stomach. The pancreas release enzymes that aid digestion and produces hormones that help manage blood sugar. Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. Several types of growth can occur in the pancreas, including cancerous and noncancerous tumors. The most common type of cancer that forms in the pancreas begins in the cells that line the ducts that carry digestive enzymes out of the pancreas (pancreatic ductal adenocarcinoma). Pancreatic cancer is seldom detected at its early stages when it is most curable, and this is because it often does not cause symptoms until after it has spread to other organs. Pancreatic cancer treatment options are chosen based on the extent of the cancer. Options may include surgery, chemotherapy, radiation therapy, or a combination of these.

 

Pancreatic cancer occurs when cells in the pancreas develop changes (mutations) in their DNA. A cell’s DNA contains the instructions that tell a cell what to do. These mutations tell the cells to grow uncontrollably and to continue living after normal cells would die. These accumulating cells can form a tumor. When left untreated, pancreatic cancer cells can spread to nearby organs, blood vessels, and distant body parts.

Continued in the report…

 

Pancreatic Cancer Diagnosis

Pancreatic cancer is difficult to diagnose because the symptoms of pancreatic cancer are often mistaken for those of other illnesses, such as irritable bowel syndrome. It may go undetected until it’s advanced. By the time symptoms occur, diagnosing pancreatic cancer is usually relatively straightforward; unfortunately, a cure is rarely possible. Diagnosing pancreatic cancer usually happens when someone comes to the doctor after experiencing weeks or months of symptoms. Pancreatic cancer symptoms frequently include abdominal pain, weight loss, itching, or jaundice (yellow skin). It is crucially important that patients are diagnosed as early as possible because early diagnosis can increase the chance of a patient having surgery to remove the tumor – currently the only potential cure. At present, only around 10% of cases are eligible for resectional surgery.

 

Multiple biomarkers based on mutation panels, antibodies, circulating DNA, microRNAs, proteins, metabolites, methylated DNA, and exosomes have been tested for pancreatic cancer screening; however, they suffer from a lack of application in longitudinal screening of asymptomatic individuals and are still not ready for clinical use, except for one. Carbohydrate antigen 19-9 (CA 19-9) is the only tumor marker approved by the US Food and Drug Administration (FDA) and used for treatment monitoring in pancreatic cancer.

Continued in the report…

 

Pancreatic Cancer Treatment

For the treatment of pancreatic cancer, the following groups are used to plan the treatment.

  • Resectable pancreatic cancer - Resectable pancreatic cancer can be removed by surgery because it has not grown into important blood vessels near the tumor.
  • Borderline resectable pancreatic cancer - Borderline resectable pancreatic cancer has grown into a major blood vessel or nearby tissue or organs. It may be possible to remove the tumor, but there is a high risk that all of the cancer cells will not be removed with surgery.
  • Locally advanced pancreatic cancer - Locally advanced pancreatic cancer has grown into or close to nearby lymph nodes or blood vessels, so surgery cannot completely remove cancer.
  • Metastatic pancreatic cancer - Metastatic pancreatic cancer has spread to other organs, so surgery cannot completely remove cancer.
  • Recurrent pancreatic cancer - Recurrent pancreatic cancer has recurred (come back) after it has been treated. Cancer may come back in the pancreas or in other parts of the body.

 

Patients with pancreatic cancer can choose from a variety of treatments. Clinical trials are being conducted to test various treatments, some of which are standard (currently used treatments). A new treatment might replace the standard one if clinical trials reveal that it is superior to the current one. Patients might consider participating in a clinical trial. Only patients who have not begun therapy are eligible for some clinical studies.

 

Five types of standard treatment that are used for pancreatic cancer are as follows.

 

Surgery

Surgery for pancreatic cancer includes removing all or part of the pancreas, depending on the location and size of the tumor in the pancreas. An area of healthy tissue around the tumor is also often removed. This is called a margin. A goal of surgery is to have “clear margins” or “negative margins,” which means that there are no cancer cells on the edges of the healthy tissue removed.

 

About 20% of people diagnosed with pancreatic cancer can have surgery because most pancreatic cancers are found after the disease has already spread. Surgery for pancreatic cancer may be combined with systemic therapy and/or radiation therapy. Typically, these additional treatments are given after surgery, which is called adjuvant therapy. However, systemic therapy and/or radiation therapy may sometimes be used before surgery to shrink a tumor, and this is called neoadjuvant therapy or preoperative therapy. After neoadjuvant therapy, the tumor is re-staged before planning surgery. Re-staging is usually done with another CT scan to look at the change in tumor size and what nearby structures and blood vessels it is affecting.

Continued in the report…..

Pancreatic Cancer Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Pancreatic Cancer, Molecular Alteration-specific Incident Cases of Pancreatic Cancer, and Stage-specific Incident Cases of Pancreatic Cancer scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

Key Findings

  • In 2021, the total incident cases of pancreatic cancer in the 7MM countries were 175,767 cases, and these cases are anticipated to increase during the study period.
  • Among the European countries, Germany had the highest incident cases of pancreatic cancer in 2021, i.e., 21,859 cases, followed by France which had 14,989 incident cases in 2021. On the other hand, Spain had the lowest incident cases of pancreatic cancer, i.e. 8,566 cases in 2021. Japan had 43,170 incident cases of pancreatic cancer in 2021.
  • In terms of stage-specific incident cases, maximum number of patients were observed for distant pancreatic cancer. This was followed by regional and localized pancreatic cancer.
  • According to DelveInsight, majority of pancreatic cancer cases are caused by KRAS2 mutation followed by TP53 and SMAD4/DPC4 mutations. Least number of incident cases were observed for pancreatic cancer associated with NTRK mutation.

Pancreatic Cancer Epidemiology

 

Country-Wise Pancreatic Cancer Epidemiology

The epidemiology segment provides the pancreatic cancer epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Pancreatic Cancer Drug Chapters

Pancreatic Cancer Emerging Drugs

 

OSE2101: OSE Immunotherapeutics

OSE2101 is a therapeutic neo-epitope-based vaccine. It is a proprietary combination of nine optimized neo-epitopes, selected and optimized from five tumoral antigens to activate specifically T-cells, plus one epitope giving universal helper T-cell response targeting T-cell activation. Phase II study TEDOPAM compares Tedopi in combination with FOLFIRI chemotherapy versus FOLFIRI, in maintenance treatment after treatment with FOLFIRINOX. The primary endpoint of the trial is the 1-year survival rate.

Products detail in the report…

 

Motixafortide (BL-8040): BioLineRx

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4 is a well-validated therapeutic target involved in the mobilization and trafficking of hematopoietic stem cells, immune cells, and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications, including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.

Products detail in the report…

 

Anktiva (N-803): ImmunityBio

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T-cells. N-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Its mechanism of action is direct specific stimulation of CD8 + T-cells and NK cells through beta-gamma T cell receptor binding (not alpha) while avoiding T-reg stimulation. N-803 has improved pharmacokinetic properties, longer persistence in lymphoid tissues, and enhanced anti-tumor activity compared to native, non-complexed IL-15 in vivo.

Products detail in the report…

 

SBP-101: Panbela Therapeutics

SBP-101 is a proprietary polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Laboratory studies suggest the primary mechanism of action of SBP-101 is driven by its enhanced uptake in pancreatic cancer cells and, potentially, other cancer cell types, resulting in disruption of normal polyamine metabolism. SBP-101 is also taken up preferentially by the exocrine pancreas, the liver, and kidneys. Importantly, pancreatic islet cells, which secrete insulin and are structurally and functionally dissimilar to acinar cells, are not impacted by SBP-101.

Products detail in the report…

List to be continued in the report…

Pancreatic Cancer Market

Pancreatic Cancer Market Outlook

Pancreatic cancer is enlisted as one of the most common cancers and the seventh-highest cause of cancer mortality worldwide. The incidence of pancreatic cancer is increasing in the Western world. The incidence of pancreatic adenocarcinoma is rising in the developed world, and modifiable lifestyle factors such as alcohol and obesity may play an essential role. The five-year survival from this disease is as low as 2% in some countries, despite improvements in surgical technique, chemotherapy regimens, and the introduction of neoadjuvant chemoradiotherapy. Currently, the main therapeutic approach for pancreatic cancer patients is majorly based on chemotherapy.

 

Pancreatic ductal adenocarcinoma (PDAC) patients constitute the major portion of the pancreatic cancer-affected population. Although advancements have been made in operative techniques and chemotherapy with time, survival rates for pancreatic cancer patients remain low. Diagnosis of pancreatic cancer in the late or advance stage i.e. Stage III, and Stage IV is the main reason for low survival. Many patients are not eligible for the treatment by this time, and in most patients, the tumor has become metastatic. Surgery can be efficiently utilized in patients with cancer in localized or regional states, and the proportion of such patients is generally low at the time of diagnosis. In the study conducted by Kasumova et al. (2017), pancreatic cancer was diagnosed in Stage I/II in only around 35% of the patients, whereas, in the remaining patients, pancreatic cancer is diagnosed at Stage III/IV. Among the patients who had disease diagnosed in Stage I/II, only 54.5% of Stage I and 43.4% of Stage II patients had undergone tumor resection. In this study, it was also reported that there had been an increase in the use of neoadjuvant therapy in Stage I and II diagnosed pancreatic cancer patients. In the case of the patients having pancreatic cancer in the advanced stage, only 68.4% and 56.9% of patients with Stage III and IV disease, respectively, received chemotherapy and/or radiation therapy.

Continued in the report…..

 

Key Findings

  • The market size of pancreatic cancer in the 7MM was observed to be of USD 1,649 million in 2021.
  • In 2021, the market size of pancreatic cancer in the US was of USD 858 million. Among the EU-5 countries, Germany had the highest market size for pancreatic cancer in 2021, i.e., USD 165 million. The lowest market size was estimated in Spain with USD 61 million in 2021.
  • In Japan, the market size of pancreatic cancer was observed to be of USD 270 million in 2021.
  • The United States and Japan account for 52% and 16% respectively of the total market size among the 7MM countries in 2021.
  • Among all the available therapies, in 2021, the highest market was captured by FOLFIRINOX with a market size of USD 569 million, whereas the minimum market capture was by S1 combination therapy in the 7MM.
  • The overall market size of gemcitabine (including monotherapy, and all combinations) in the pancreatic cancer space was of USD 625 million in 2021.

 

The United States Market Outlook

This section provides the total pancreatic cancer market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total pancreatic cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total pancreatic cancer market size and market size by therapies in Japan are provided.

Pancreatic Cancer Market Share

 

Pancreatic Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the pancreatic cancer market or expected to get launched in the market during the study period 2019–2032. The analysis covers the pancreatic cancer market uptake by drugs; patient uptake by therapies; and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Pancreatic Cancer Development Activities

The pancreatic cancer pipeline report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for pancreatic cancer emerging therapies.

 

Reimbursement Scenario in Pancreatic Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

Competitive Intelligence Analysis

We perform competitive market Intelligence analysis of the pancreatic cancer market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 1,649 Million in 2021

Key Companies

AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb, and others

Scope of the Report

  • The report covers the descriptive overview of pancreatic cancer, explaining its causes, symptoms, pathophysiology, genetic basis, diagnosis, and currently available therapies.
  • Comprehensive insight has been provided into the pancreatic cancer epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for pancreatic cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the pancreatic cancer market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM pancreatic cancer market.

 

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing incidence, and effectiveness of drugs will positively drive the pancreatic cancer market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence pancreatic cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for pancreatic cancer. The launch of emerging therapies will significantly impact the pancreatic cancer market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Pancreatic Cancer Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pancreatic Cancer Pipeline Analysis
  • Pancreatic Cancer Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

 

Pancreatic Cancer Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Pancreatic Cancer Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

 

Pancreatic Cancer Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • SWOT analysis

 

Key Questions

Market Insights:

  • What was the pancreatic cancer market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the pancreatic cancer total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest pancreatic cancer market size during the forecast period (2022–2032)?
  • At what CAGR, the pancreatic cancer market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the pancreatic cancer market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the pancreatic cancer market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of pancreatic cancer?
  • What is the historical pancreatic cancer patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of pancreatic cancer at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to pancreatic cancer?
  • Out of the above-mentioned countries, which country would have the highest population of pancreatic cancer during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of pancreatic cancer along with the approved therapy?
  • What are the current treatment guidelines for the treatment of pancreatic cancer?
  • What are the pancreatic cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of pancreatic cancer?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of pancreatic cancer?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the pancreatic cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for pancreatic cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for pancreatic cancer?
  • What are the 7MM historical and forecasted market of pancreatic cancer?

 

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving pancreatic cancer.
  • To understand the future market competition in the pancreatic cancer market and an insightful review of the market.
  • Organize sales and marketing efforts by identifying the best opportunities for pancreatic cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the pancreatic cancer market.
  • To understand the future market competition in the pancreatic cancer market.

1. Key Insights

2. Report Introduction

3. Pancreatic Cancer-Market Overview at a Glance

3.1. Market Share (%) Pancreatic Cancer by Therapies in 2019

3.2. Market Share (%) of Pancreatic Cancer by Therapies in 2032

4. Pancreatic Cancer - Future Prospects

5. Executive Summary of Pancreatic Cancer

6. Key Events

7. Disease Background and Overview

7.1. Introduction

7.2. Types of Pancreatic Cancer

7.3. Stages of Pancreatic Cancer

7.4. Signs and Symptoms

7.5. Risk Factors and Causes

7.6. Pathophysiology/Mechanisms

7.6.1. Carcinogenesis and Molecular Biology

7.6.2. Molecular Genetics of Pancreatic Cancer

7.7. Diagnosis

7.7.1. Differential Diagnosis

7.8. Diagnostic Algorithm

7.9. Diagnostic Guidelines

7.9.1. ASGE Guideline on Screening for Pancreatic Cancer in Individuals With Genetic Susceptibility, 2022

7.9.2. Metastatic Pancreatic Cancer: ASCO Guideline, 2020

7.9.3. National Institute for Health and Care Excellence, NICE, 2022

7.9.4. Clinical Practice Guidelines for Diagnosis of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM), 2020

7.9.5. Clinical Practice Guidelines for Pancreatic Cancer 2019 from the Japan Pancreas Society

8. Treatment and Management

8.1. Treatment Options by Pancreatic Cancer Stage

8.2. Treatment Algorithm

8.3. Treatment Guidelines for Pancreatic cancer

8.3.1. NCCN Guidelines for the Treatment of Pancreatic Adenocarcinoma, 2022

8.3.2. Metastatic Pancreatic Cancer: ASCO Guideline, 2020

8.3.3. SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)

8.3.4. Clinical Practice Guidelines for Diagnosis of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM), 2020

8.3.5. Clinical Practice Guidelines for Pancreatic Cancer 2019 from the Japan Pancreas Society

9. Methodology

10. Epidemiology and Patient Population

10.1. Key Findings

10.2. Assumptions and Rationale 7MM

10.3. Total Incident Cases of Pancreatic Cancer in the 7MM

10.4. The United States

10.4.1. Total Incident Cases of Pancreatic Cancer in the United States

10.4.2. Molecular Alteration-specific Incident Cases of Pancreatic Cancer in the United States

10.4.3. Stage-specific Incident Cases of Pancreatic Cancer in the United States

10.5. EU-5

10.5.1. Total Incident Cases of Pancreatic Cancer in EU-5

10.5.2. Molecular Alteration-specific Incident Cases of Pancreatic Cancer in EU-5

10.5.3. Stage-specific Incident Cases of Pancreatic Cancer in EU-5

10.6. Japan

10.6.1. Total Incident Cases of Pancreatic Cancer in Japan

10.6.2. Molecular Alteration-specific Incident Cases of Pancreatic Cancer in Japan

10.6.3. Stage-specific Incident Cases of Pancreatic Cancer in Japan

11. Patient Journey

12. Marketed Products

12.1. Key-cross

12.2. Lynparza (olaparib): AstraZeneca

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Other Developmental Activity

12.2.4. Clinical Developmental Activities

12.2.4.1. Clinical Trials Information

12.2.5. Safety and Efficacy

12.3. Keytruda (pembrolizumab): Merck Sharp & Dohme LLC

12.3.1. Product Description

12.3.2. Regulatory Milestones

12.3.3. Other Developmental Activities

12.3.4. Clinical Developmental Activities

12.3.4.1. Clinical Trials Information

12.3.5. Safety and Efficacy

12.4. Vitrakvi (larotrectinib): Bayer

12.4.1. Product Description

12.4.2. Regulatory Milestones

12.4.3. Other Developmental Activities

12.4.4. Clinical Developmental Activities

12.4.4.1. Clinical Trials Information

12.4.5. Safety and Efficacy

12.5. Rozlytrek (entrectinib): Roche

12.5.1. Product Description

12.5.2. Regulatory Milestones

12.5.3. Other Developmental Activities

12.5.4. Clinical Developmental Activities

12.5.4.1. Clinical Trials Information

12.5.5. Safety and Efficacy

12.6. Abraxane (nab-paclitaxel): Celgene/Bristol Myers Squibb

12.6.1. Product Description

12.6.2. Regulatory Milestones

12.6.3. Other Developmental Activities

12.6.4. Clinical Developmental Activities

12.6.4.1. Clinical Trials Information

12.6.5. Safety and Efficacy

13. Emerging Therapies

13.1. Key Cross Competition

13.2. Motixafortide (BL-8040): BioLineRx/Merck Sharp & Dohme

13.2.1. Product description

13.2.2. Other developmental activity

13.2.3. Clinical developmental activities

13.2.3.1. Clinical trials information

13.2.4. Safety and efficacy

13.3. Mitazalimab (ADC-1013): Alligator Bioscience

13.3.1. Product description

13.3.2. Other developmental activity

13.3.3. Clinical developmental activities

13.3.3.1. Clinical trials information

13.3.4. Safety and Efficacy

13.4. BPX-601: Bellicum Pharmaceuticals

13.4.1. Product description

13.4.2. Other developmental activity

13.4.3. Clinical developmental activities

13.4.3.1. Clinical trials information

13.4.4. Safety and efficacy

13.5. Tedopi (OSE2101): OSE Immunotherapeutics

13.5.1. Product description

13.5.2. Other developmental activity

13.5.3. Clinical developmental activities

13.5.3.1. Clinical trials information

13.5.4. Safety and efficacy

13.6. AZD5305: Astra Zeneca

13.6.1. Product description

13.6.2. Clinical developmental activities

13.6.2.1. Clinical trials information

13.6.3. Safety and efficacy

13.7. Elraglusib (9 ING 41): Actuate Therapeutics

13.7.1. Product description

13.7.2. Other developmental activity

13.7.3. Clinical developmental activities

13.7.3.1. Clinical trials information

13.7.4. Safety and efficacy

13.8. Pamrevlumab (FG-3019): FibroGen

13.8.1. Product description

13.8.2. Other developmental activity

13.8.3. Clinical developmental activities

13.8.3.1. Clinical trials information

13.8.4. Safety and efficacy

13.9. NT-I7 (Efineptakin Alfa): NeoImmuneTech

13.9.1. Product Description

13.9.2. Other Developmental Activity

13.9.3. Clinical Developmental Activities

13.9.3.1. Clinical Trials Information

13.9.4. Safety and Efficacy

13.10. Olaptesed pegol (NOX-A12): NOXXON Pharma

13.10.1. Product description

13.10.2. Other developmental activity

13.10.3. Clinical developmental activities

13.10.3.1. Clinical trials information

13.10.4. Safety and efficacy

13.11. siG12D LODER: Silenseed Ltd.

13.11.1. Product description

13.11.2. Other developmental activity

13.11.3. Clinical developmental activities

13.11.3.1. Clinical trials information

13.11.4. Safety and efficacy

13.12. Sotorasib (LUMAKRAS/AMG 510): Amgen

13.12.1. Product description

13.12.2. Other developmental activity

13.12.3. Clinical developmental activities

13.12.3.1. Clinical trials information

13.12.4. Safety and efficacy

13.13. NGM120: NGM Biopharmaceuticals

13.13.1. Product description

13.13.2. Other developmental activity

13.13.3. Clinical developmental activities

13.13.3.1. Clinical trials information

13.13.4. Safety and Efficacy

13.14. Zenocutuzumab (Zeno, MCLA-128): Merus

13.14.1. Product description

13.14.2. Other developmental activities

13.14.3. Clinical developmental activities

13.14.3.1. Clinical trials information

13.14.4. Safety and Efficacy

13.15. Adagrasib (MRTX849): Mirati Therapeutics

13.15.1. Product description

13.15.2. Other developmental activities

13.15.3. Clinical developmental activities

13.15.3.1. Clinical trials information

13.15.4. Safety and Efficacy

13.16. RX-3117: Rexahn Pharmaceuticals/Ocuphire Pharma/Processa Pharmaceuticals

13.16.1. Product description

13.16.2. Other developmental activities

13.16.3. Clinical developmental activities

13.16.3.1. Clinical trials information

13.16.4. Safety and efficacy

13.17. Anktiva (N-803): ImmunityBio

13.17.1. Product description

13.17.2. Other Developmental Activities

13.17.3. Clinical developmental activities

13.17.3.1. Clinical trials information

13.17.4. Safety and efficacy

13.18. BPM31510 (ubidecarenone): Berg

13.18.1. Product description

13.18.2. Other developmental activities

13.18.3. Clinical developmental activities

13.18.3.1. Clinical trials information

13.18.4. Safety and efficacy

13.19. SBP-101: Panbela Therapeutics

13.19.1. Product description

13.19.2. Other developmental activities

13.19.3. Clinical developmental activities

13.19.3.1. Clinical trials information

13.19.4. Safety and efficacy

13.20. Zejula (niraparib): GlaxoSmithKline/Bristol Myers Squibb

13.20.1. Product description

13.20.2. Other developmental activities

13.20.3. Clinical developmental activities

13.20.3.1. Clinical trials information

13.20.4. Safety and efficacy

13.21. Glufosfamide: Eleison Pharmaceuticals/Molecular Templates

13.21.1. Product description

13.21.2. Other developmental activities

13.21.3. Clinical developmental activities

13.21.3.1. Clinical trials information

13.21.4. Results

13.22. LOAd703 (delolimogene mupadenorepvec): Lokon Pharma AB

13.22.1. Product description

13.22.2. Other developmental activities

13.22.3. Clinical developmental activities

13.22.3.1. Clinical trials information

13.22.4. Safety and efficacy

13.23. CAN04 (Nadunolimab): Cantargia AB

13.23.1. Product description

13.23.2. Other developmental activities

13.23.3. Clinical developmental activities

13.23.3.1. Clinical trials information

13.23.4. Safety and efficacy

13.24. GVAX Pancreatic Tumor Vaccine: Bristol-Myers Squibb

13.24.1. Product Description

13.24.2. Clinical developmental activities

13.24.2.1. Clinical trials information

13.24.3. Safety and efficacy

14. Pancreatic Cancer: Seven Major Market Analysis

14.1. Key Findings

14.3. Market Outlook

14.4. Attribute Analysis

14.5. Key Market Forecast Assumptions

14.6. Market size of Pancreatic Cancer in the 7MM

14.7. Market size of Pancreatic Cancer by Therapies in the 7MM

14.8. Market size of Pancreatic Cancer in the United States

14.8.1. Total Market size of Pancreatic Cancer

14.8.2. Market Size of Pancreatic Cancer by Therapies

14.8.2.1. Market Size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in the United States

14.8.2.2. Market Size of Pancreatic Cancer by Therapies (First-line) in the United States

14.8.2.3. Market Size of Pancreatic Cancer by Therapies (Second-line plus) in the United States

14.9. Market Size of Pancreatic Cancer in EU-5

14.9.1. Total Market Size of Pancreatic Cancer

14.9.2. Market Size of Pancreatic Cancer by Therapies

14.9.2.1. Market Size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in EU-5

14.9.2.2. Market Size of Pancreatic Cancer by Therapies (First-line) in EU-5

14.9.2.3. Market Size of Pancreatic Cancer by Therapies (Second-line plus) in EU-5

14.10. Market Size of Pancreatic Cancer in Japan

14.10.1. Total Market Size of Pancreatic Cancer

14.10.2. Market Size of Pancreatic Cancer by Therapies

14.10.2.1. Market Size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in Japan

14.10.2.2. Market Size of Pancreatic Cancer by Therapies (First-line) in Japan

14.10.2.3. Market Size of Pancreatic Cancer by Therapies (Second-line plus) in Japan

15. Market Access and Reimbursement

15.1. Reimbursement

15.2. Key HTA Decisions

15.3. Patient Access Program

16. KOL Views

17. SWOT Analysis

18. Unmet Needs

19. Appendix

19.1. Report Methodology

19.2. Bibliography

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Table

Table 1: Summary of Pancreatic Cancer (2019–2032)

Table 2: Key Events

Table 3: Total Incident Cases of Pancreatic Cancer in the 7MM (2019–2032)

Table 4: Total Incident Cases of Pancreatic Cancer in the United States (2019–2032)

Table 5: Molecular Alteration-specific Incident Cases of Pancreatic Cancer in the United States (2019–2032)

Table 6: Stage-specific Incident Cases of Pancreatic Cancer in the United States (2019–2032)

Table 7: Total Incident Cases of Pancreatic Cancer in EU-5 (2019–2032)

Table 8: Molecular Alteration-specific Incident Cases of Pancreatic Cancer in EU-5 (2019–2032)

Table 9: Stage-specific Incident Cases of Pancreatic Cancer in EU-5 (2019–2032)

Table 10: Total Incident Cases of Pancreatic Cancer in Japan (2019–2032)

Table 11: Molecular Alteration-specific Incident Cases of Pancreatic Cancer in Japan (2019–2032)

Table 12: Stage-specific Incident Cases of Pancreatic Cancer in Japan (2019–2032)

Table 13: Key cross competition - Marketed drugs

Table 14: Lynparza (olaparib), Clinical Trial Description, 2022

Table 15: Efficacy Results - POLO (BICR-assessed)

Table 16: Keytruda (pembrolizumab), Clinical Trial Description, 2022

Table 17: Efficacy Results for Patients with MSI-H/dMMR Cancer

Table 18: Response by Tumor Type

Table 19: Vitrakvi (larotrectinib), Clinical Trial Description, 2022

Table 20: Efficacy Results for Patients with Solid Tumors Harboring NTRK Gene Fusions

Table 21: Efficacy Results by Tumor Type

Table 22: Efficacy Results by NTRK Fusion Partner

Table 23: Rozlytrek (entrectinib), Clinical Trial Description, 2022

Table 24: Efficacy Results for Patients with Solid Tumors Harboring NTRK Gene Fusions

Table 25: Efficacy by Tumor Type

Table 26: Efficacy Results by NTRK Gene Fusion Partner

Table 27: Abraxane (nab-paclitaxel), Clinical Trial Description, 2022

Table 28: Efficacy Results from Randomized Study in Patients with Adenocarcinoma of the Pancreas (ITT Population)

Table 29: Key cross competition-  Emerging Therapies Included in the Model

Table 30: Key cross competition

Table 31: Motixafortide (BL-8040), Clinical Trial Description, 2022

Table 32: Mitazalimab (ADC-1013), Clinical Trial Description, 2022

Table 33: BPX-601, Clinical Trial Description, 2022

Table 34: Tedopi (OSE2101), Clinical Trial Description, 2022

Table 35: Other Efficacy Results

Table 36: AZD5305, Clinical Trial Description, 2022

Table 37: Elraglusib (9 ING 41), Clinical Trial Description, 2022

Table 38: Pamrevlumab (FG-3019), Clinical Trial Description, 2022

Table 39: NT-I7 (Efineptakin Alfa), Clinical Trial Description, 2022

Table 40: Olaptesed pegol (NOX-A12), Clinical Trial Description, 2022

Table 41: siG12D LODER, Clinical Trial Description, 2022

Table 42: Sotorasib (LUMAKRAS/AMG 510), Clinical Trial Description, 2022

Table 43: NGM120, Clinical Trial Description, 2022

Table 44: Zenocutuzumab (Zeno, MCLA-128), Clinical Trial Description, 2022

Table 45: Adagrasib ( MRTX849), Clinical Trial Description, 2022

Table 46: RX-3117, Clinical Trial Description, 2022

Table 47: N-803, Clinical Trial Description, 2022

Table 48: BPM31510 (ubidecarenone), Clinical Trial Description, 2022

Table 49: SBP-101, Clinical Trial Description, 2022

Table 50: Zejula (niraparib); Clinical Trial Description, 2022

Table 51: Efficacy Results

Table 52: Glufosfamide; Clinical Trial Description, 2022

Table 53: LOAd703 (delolimogene mupadenorepvec); Clinical Trial Description, 2022

Table 54: CAN04; Clinical Trial Description, 2022

Table 55: GVAX Pancreatic Tumor Vaccine, Clinical Trial Description, 2022

Table 56: Key Market Forecast Assumptions for Tedopi (OSE2101)

Table 57: Key Market Forecast Assumptions for Anktiva (N-803)

Table 58: Key Market Forecast Assumptions for Sotorasib

Table 59: Key Market Forecast Assumptions for Zenocutuzumab (MCLA-128)

Table 60: Key Market Forecast Assumptions for SBP-101

Table 61: Key Market Forecast Assumptions for LOAd703

Table 62: Key Market Forecast Assumptions for CAN04

Table 63: Key Market Forecast Assumptions for Zejula (Niraparib)

Table 64: Key Market Forecast Assumptions for Keytruda (pembrolizumab)

Table 65: Key Market Forecast Assumptions for Motixafortide (BL-8040)

Table 66: Key Market Forecast Assumptions for GVAX

Table 67: Key Market Forecast Assumptions for Pamrevlumab

Table 68: Seven Major Market Size of Pancreatic Cancer in USD Million (2019–2032)

Table 69: Market Size of Pancreatic Cancer by Therapies in the 7MM, USD Million (2019–2032)

Table 70: Total Market Size of Pancreatic Cancer in the United States, USD Millions (2019–2032)

Table 71: Market Size of Pancreatic Cancer by Therapies in the United States, USD Million (2019–2032)

Table 72: Market Size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in the United States, USD Million (2019–2032)

Table 73: Market Size of Pancreatic Cancer by Therapies in the United States (First-line), in USD Million (2019–2032)

Table 74: Market Size of Pancreatic Cancer by Therapies (Second-line plus) in the United States, USD Million (2019–2032)

Table 75: Total Market Size of Pancreatic Cancer in EU-5, USD Million (2019–2032)

Table 76: Market Size of Pancreatic Cancer by therapies in EU-5, in USD Million (2019–2032)

Table 77: Market size of Pancreatic Cancer by therapies (Adjuvant/Neo-adjuvant)  in EU-5, USD Million (2019–2032)

Table 78: Market Size of Pancreatic Cancer by Therapies (First-line) in EU-5, USD Million (2019–2032)

Table 79: Market Size of Pancreatic Cancer by Therapies (Second-line plus) in EU-5, USD Million (2019–2032)

Table 80: Total Market Size of Pancreatic Cancer in Japan, USD Millions (2019–2032)

Table 81: Market Size of Pancreatic Cancer by Therapies in Japan, USD Million (2019–2032)

Table 82: Market size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in Japan, USD Million (2019–2032)

Table 83: Market size of Pancreatic Cancer by Therapies in Japan (First-line), USD Million (2019–2032)

Table 84: Market size of Pancreatic Cancer by therapies in Japan (Second-line plus), in USD Million (2019–2032)

Table 85: Key HTA Decisions

List of Figures

Figure 1: Pancreatic Cancer

Figure 2: Anatomy of the Pancreas

Figure 3: Types of Pancreatic Cancer

Figure 4: Stage 0 Pancreatic Cancer

Figure 5: Stage I Pancreatic Cancer

Figure 6: Stage IIA Pancreatic Cancer

Figure 7: Stage IIB Pancreatic Cancer

Figure 8: Stage III Pancreatic Cancer

Figure 9: Stage IV Pancreatic Cancer

Figure 10: Signs and Symptoms of Pancreatic Cancer

Figure 11: Risk Factors of Pancreatic Cancer

Figure 12: Pathways of Key Driver Genes and Therapeutic Targets in Pancreatic Cancer

Figure 13: Biomarkers Studies in Early Detection of Pancreatic Cancer

Figure 14: Algorithm for Diagnosis of Pancreatic cancer

Figure 15: Algorithm for Treatment of Pancreatic cancer

Figure 16: Algorithm for chemotherapy of pancreatic cancer

Figure 17: NCCN Guidelines for Resectable Disease

Figure 18: NCCN Guidelines for Borderline Resectable Disease

Figure 19: NCCN Guidelines for Locally Advanced Disease

Figure 20: NCCN Guidelines for Metastatic Disease

Figure 21: Total Incident Cases of Pancreatic Cancer in the 7MM (2019–2032)

Figure 22: Total Incident Cases of Pancreatic Cancer in the United States (2019–2032)

Figure 23: Molecular Alteration-specific Incident Cases of Pancreatic Cancer in the United States (2019–2032)

Figure 24: Stage-specific Incident Cases of Pancreatic Cancer in the United States (2019–2032)

Figure 25: Total Incident Cases of Pancreatic Cancer in EU-5 (2019–2032)

Figure 26: Molecular Alteration-specific Incident Cases of Pancreatic Cancer in EU-5 (2019–2032)

Figure 27: Stage-specific Incident Cases of Pancreatic Cancer in EU-5 (2019–2032)

Figure 28: Total Incident Cases of Pancreatic Cancer in Japan (2019–2032)

Figure 29: Molecular Alteration-specific Incident Cases of Pancreatic Cancer in Japan (2019–2032)

Figure 30: Stage-specific Incident Cases of Pancreatic Cancer in Japan (2019–2032)

Figure 31: Kaplan–Meier Curves of BICR-Assessed Progression-Free Survival – POLO

Figure 32: Kaplan–Meier Curve of Overall Survival (Intent-to-Treat Population)

Figure 33: Increased neutralization of CXCL12 by NOX-A12 correlates with immune activation and clinical benefit

Figure 34: Mechanism of action of zenocutuzumab

Figure 35: Market Size of Pancreatic Cancer, USD Millions (2019–2032)

Figure 36: Market Size of Pancreatic Cancer by Therapies in the 7MM, USD Millions (2019–2032)

Figure 37: Total Market Size of Pancreatic Cancer in the United States, USD Millions (2019–2032)

Figure 38: Market Size of Pancreatic Cancer by Therapies in the United States, USD Million (2019–2032)

Figure 39: Market Size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in the United States, USD Million (2019–2032)

Figure 40: Market Size of Pancreatic Cancer by Therapies (First-line) in the United States, USD Million (2019–2032)

Figure 41: Market Size of Pancreatic Cancer by Therapies (Second-line plus) in the United States, in USD Million (2019–2032)

Figure 42: Total Market Size of Pancreatic Cancer in EU-5, USD Millions (2019–2032)

Figure 43: Market Size of Pancreatic Cancer by Therapies in EU-5, USD Million (2019–2032)

Figure 44: Market size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in EU-5, USD Million (2019–2032)

Figure 45: Market Size of Pancreatic Cancer by Therapies (First-line) in EU-5, USD Million (2019–2032)

Figure 46: Market Size of Pancreatic Cancer by Therapies (Second-line plus) in EU-5, USD Million (2019–2032)

Figure 47: Total Market Size of Pancreatic Cancer in Japan, USD Millions (2019–2032)

Figure 48: Market Size of Pancreatic Cancer by Therapies in Japan, USD Million (2019–2032)

Figure 49: Market size of Pancreatic Cancer by Therapies (Adjuvant/Neo-adjuvant) in Japan, USD Million (2019–2032)

Figure 50: Market size of Pancreatic Cancer by Therapies in Japan (First-line), USD Million (2019–2032)

Figure 51: Market Size of Pancreatic Cancer by Therapies (Second-line plus) in Japan, USD Million (2019–2032)

Figure 52: Unmet Needs

AstraZeneca
Merck Sharp & Dohme LLC
Bayer
Roche
Celgene
Bristol Myers Squibb
BioLineRx
Alligator Bioscience
Bellicum Pharmaceuticals
OSE Immunotherapeutics
Actuate Therapeutics
FibroGen
NeoImmuneTech
NOXXON Pharma
Silenseed Ltd.
Amgen
NGM Biopharmaceuticals
Merus
Mirati Therapeutics
Rexahn Pharmaceuticals
Ocuphire Pharma
Processa Pharmaceuticals
ImmunityBio
Berg
Panbela Therapeutics
GlaxoSmithKline
Eleison Pharmaceuticals
Molecular Templates
Lokon Pharma AB
Cantargia AB
Bristol-Myers Squibb

 

Forward to Friend

Need A Quote